Literature DB >> 30127492

Economic sustainability of immune-checkpoint inhibitors: the looming threat.

Vivek Verma1.   

Abstract

Mesh：

Year:  2018        PMID： 30127492     DOI： 10.1038/s41571-018-0086-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

Review 1.  Embracing nanomaterials' interactions with the innate immune system.

Authors:  Abraham J P Teunissen; Marianne E Burnett; Geoffrey Prévot; Emma D Klein; Daniel Bivona; Willem J M Mulder
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-04-13

Review 2.  A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.

Authors:  Vivek Verma; Tanja Sprave; Waqar Haque; Charles B Simone; Joe Y Chang; James W Welsh; Charles R Thomas
Journal:  J Immunother Cancer       Date:  2018-11-23       Impact factor: 13.751

3.  Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer.

Authors:  Waqar Haque; Vivek Verma; Sebastian Adeberg; Robert Rustomily; Simon Lo; E Brian Butler; Bin S Teh
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09

4.  Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.

Authors:  Bora Youn; Ira B Wilson; Vincent Mor; Nikolaos A Trikalinos; Issa J Dahabreh
Journal:  Health Serv Res       Date:  2021-03-07       Impact factor: 3.734
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.